Pre-exposure prophylaxis for HIV: effective and underused

Hempel, Amanda; Biondi, Mia J; Baril, Jean‐Guy; Tan, Darrell H. S.

doi:10.1503/cmaj.220645

CMAJ

2022

DOI: 10.1503/cmaj.220645

|View full text |Cite

Pre-exposure prophylaxis for HIV: effective and underused

Amanda Hempel

Mia J Biondi

Jean‐Guy Baril

et al.

Abstract: Preexposure prophylaxis (PrEP) is a highly effective modality for HIV prevention that can be prescribed by generalists.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Has the switch to sexual risk behaviour screening impacted deferrals for pre‐ and post‐exposure prophylaxis therapy for human immunodeficiency virus?

Goldman,

Uzicanin,

O'Brien

2024

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesCanadian Blood Services defers donors during and for 4 months after oral pre‐exposure or post‐exposure prophylaxis (PrEP/PEP) for human immunodeficiency virus (HIV) because of concerns about altered viral kinetics. We assessed the impact of the switch from a time‐based deferral for men who have sex with men (MSM) to sexual risk behaviour criteria on PrEP/PEP deferrals.Materials and MethodsData on PrEP/PEP deferral codes were extracted from our National Epidemiology Database for the 22 months before (Period 1) and after (Period 2) the criteria change.ResultsPEP deferrals remained stable (2.3 vs. 1.7 per 100,000 donations in Periods 1 and 2, p = 0.2892), about 45% and 33%, respectively, of these donors who reported a recent needle stick injury. PrEP deferrals increased from 5.9 to 12.4 per 100,000 (p = 0.0001); approximately 30% of donors in both periods had other HIV risk factor deferrals. Donors deferred for PrEP use alone were more likely to be male, first‐time users and younger than other donors.ConclusionThe switch to sexual risk behaviour led to a small increase in deferrals for PrEP. We may not be measuring the full impact of deferral criteria because potential donors may self‐defer and PrEP use is increasing.

show abstract

Has the switch to sexual risk behaviour screening impacted deferrals for pre‐ and post‐exposure prophylaxis therapy for human immunodeficiency virus?

Goldman,

Uzicanin,

O'Brien

2024

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

HIV risk assessment tools for identifying individuals who could benefit from pre-exposure prophylaxis: a systematic review protocol

Oo,

Shukalek,

Kishibe

et al. 2024

BMJ Open

View full text Add to dashboard Cite

BackgroundPre-exposure prophylaxis (PrEP) is a highly effective, safe and acceptable intervention for preventing HIV infection. However, identifying individuals who could best benefit from PrEP remains a significant challenge. Existing HIV risk assessment tools vary in performance depending on context. This systematic review aims to synthesise evidence on their diagnostic performances to predict incident HIV infection.Methods and analysisThis protocol is informed and reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Protocols. We will search MEDLINE (Ovid), Embase (Ovid) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases (January 1998–May 2024) for observational and relevant interventional studies assessing the diagnostic performance of HIV risk tools to predict incident HIV for PrEP eligibility. There will be no restrictions on study language or location. Two reviewers will conduct the search, data extraction and risk of bias assessment using the Johanna Briggs Institute Critical Appraisal Checklist for Diagnostic Studies. Standardised templates will be used in Covidence for data extraction. We will conduct a meta-analysis if appropriate, otherwise, a narrative review. We will use the PRISMA guidelines to guide reporting.Ethics and dissemination of researchEthical approval is not required as data is publicly available. This review will inform updates to Canadian HIV PrEP guidelines and guide healthcare professionals in using HIV risk assessment tools for identifying PrEP candidates. Findings will be presented at guideline panel meetings and submitted for publication in a peer-reviewed journal and conferences.PROSPERO registration numberCRD42024543975.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pre-exposure prophylaxis for HIV: effective and underused

Abstract: Preexposure prophylaxis (PrEP) is a highly effective modality for HIV prevention that can be prescribed by generalists.

Cited by 2 publications

References 38 publications

Has the switch to sexual risk behaviour screening impacted deferrals for pre‐ and post‐exposure prophylaxis therapy for human immunodeficiency virus?

Has the switch to sexual risk behaviour screening impacted deferrals for pre‐ and post‐exposure prophylaxis therapy for human immunodeficiency virus?

HIV risk assessment tools for identifying individuals who could benefit from pre-exposure prophylaxis: a systematic review protocol

Contact Info

Product

Resources

About